$GLSI
Greenwich LifeSciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000149315222022956 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $659.6K $140.1K $328.4K
YoY Change 214.7% -28.87% 2.62%
% of Gross Profit
Research & Development $1.723M $633.3K $1.661M
YoY Change 162.29% 13.78% 493.15%
% of Gross Profit
Depreciation & Amortization $900.00 $910.00 $900.00
YoY Change 0.0% -49.72%
% of Gross Profit
Operating Expenses $2.383M $773.3K $1.989M
YoY Change 174.96% 2.64% 231.53%
Operating Profit -$2.383M -$773.3K -$1.989M
YoY Change 174.96% 2.64%
Interest Expense $64.04K $27.23K $19.58K
YoY Change 1693.84% 635.95%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.319M -$746.1K -$1.970M
YoY Change 168.68% -0.49% 228.27%
Income Tax
% Of Pretax Income
Net Earnings -$2.319M -$746.1K -$1.970M
YoY Change 168.68% -0.49% 229.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.06 -$0.15
Diluted Earnings Per Share -$180.8K -$57.73K -$150.8K
COMMON SHARES
Basic Shares Outstanding 12.82M shares
Diluted Shares Outstanding 12.82M shares 12.92M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.64M $17.19M $19.74M
YoY Change -45.9% -42.32% -35.06%
Cash & Equivalents $15.64M $17.19M $19.74M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.64M $17.19M $19.74M
YoY Change -45.9% -42.32% -35.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.903K $10.81K $11.71K
YoY Change -26.75% -25.04% -41.45%
TOTAL ASSETS
Total Short-Term Assets $15.64M $17.19M $19.74M
Total Long-Term Assets $9.903K $10.81K $11.71K
Total Assets $15.65M $17.20M $19.75M
YoY Change -45.89% -42.32% -35.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $220.9K $220.9K $220.9K
YoY Change -25.35% -64.81% -63.8%
Accrued Expenses $17.03K $8.290K $20.32K
YoY Change -89.31% -66.87% -66.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $237.9K $229.1K $241.2K
YoY Change -47.73% -64.89% -64.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $237.9K $229.1K $241.2K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $237.9K $229.1K $241.2K
YoY Change -47.73% -64.89% -64.0%
SHAREHOLDERS EQUITY
Retained Earnings -$38.68M -$36.36M
YoY Change
Common Stock $54.09M $53.33M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.41M $16.97M $19.51M
YoY Change
Total Liabilities & Shareholders Equity $15.65M $17.20M $19.75M
YoY Change -45.89% -42.32% -35.06%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.319M -$746.1K -$1.970M
YoY Change 168.68% -0.49% 229.92%
Depreciation, Depletion And Amortization $900.00 $910.00 $900.00
YoY Change 0.0% -49.72%
Cash From Operating Activities -$1.550M -$532.7K -$1.947M
YoY Change 73.23% -11.6% 267.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -2.023M -5.514M
YoY Change -71065.26% -342.89%
NET CHANGE
Cash From Operating Activities -1.550M -532.7K -1.947M
Cash From Investing Activities
Cash From Financing Activities 0.000 -2.023M -5.514M
Net Change In Cash -1.550M -2.555M -7.461M
YoY Change 73.23% 326.05% -528.8%
FREE CASH FLOW
Cash From Operating Activities -$1.550M -$532.7K -$1.947M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39555
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
GREENWICH LIFESCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5473709
dei Entity Address Address Line1
EntityAddressAddressLine1
3992 Bluebonnet Dr.
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 14
dei Entity Address City Or Town
EntityAddressCityOrTown
Stafford
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77477
dei City Area Code
CityAreaCode
(832)
dei Local Phone Number
LocalPhoneNumber
819-3232
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GLSI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12823713 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17187890 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27204269 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001799788
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10809 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12615 usd
CY2022Q2 us-gaap Assets
Assets
17198699 usd
CY2021Q4 us-gaap Assets
Assets
27216884 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8289 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
164327 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
229134 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
385172 usd
CY2022Q2 us-gaap Liabilities
Liabilities
229134 usd
CY2021Q4 us-gaap Liabilities
Liabilities
385172 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12774809 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12774809 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13147829 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13147829 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
12775 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13148 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
53320020 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60466093 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36363230 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33647529 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16969565 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17198699 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27216884 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
633250 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
556534 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2294071 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
838511 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
140057 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
196911 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
468439 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
515540 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
773307 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
753445 usd
us-gaap Operating Expenses
OperatingExpenses
2762510 usd
us-gaap Operating Expenses
OperatingExpenses
1354051 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-773307 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-753445 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2762510 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1354051 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
27234 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3700 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
46809 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
7298 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-746073 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-749745 usd
us-gaap Net Income Loss
NetIncomeLoss
-2715701 usd
us-gaap Net Income Loss
NetIncomeLoss
-1346753 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12923434 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12895801 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13091915 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12789326 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27631110 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
165051 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2548000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-597008 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
29747153 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
165051 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-749745 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29162459 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
165267 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5513711 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1969628 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19513640 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
224503 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2022505 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-746073 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16969565 usd
us-gaap Net Income Loss
NetIncomeLoss
-2715701 usd
us-gaap Net Income Loss
NetIncomeLoss
-1346753 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1806 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1806 usd
us-gaap Share Based Compensation
ShareBasedCompensation
389770 usd
us-gaap Share Based Compensation
ShareBasedCompensation
330102 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-120000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
36606 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-156038 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-34350 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2480163 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1132589 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2548000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7536216 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
275154 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7536216 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2272846 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10016379 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1140257 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28660375 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17187890 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29800632 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2715701 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1346753 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2715701 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1346753 usd
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13091915 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12789326 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8289 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
164327 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
819825 shares
CY2022Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2022Q2 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
25873 usd
CY2022Q2 GLSI Closing Share Price
ClosingSharePrice
8.47
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
GLSI Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInValue
9512356 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
59452 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9452904 usd

Files In Submission

Name View Source Status
0001493152-22-022956-index-headers.html Edgar Link pending
0001493152-22-022956-index.html Edgar Link pending
0001493152-22-022956.txt Edgar Link pending
0001493152-22-022956-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
glsi-20220630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
form10-q_htm.xml Edgar Link completed
glsi-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
glsi-20220630_lab.xml Edgar Link unprocessable
glsi-20220630_cal.xml Edgar Link unprocessable
glsi-20220630_def.xml Edgar Link unprocessable